| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044808114 |
| P356 | DOI | 10.1038/NCPONC1090 |
| P698 | PubMed publication ID | 18364726 |
| P2093 | author name string | Ian E Smith | |
| Sanjay Popat | |||
| P2860 | cites work | Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes | Q24308695 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity | Q28379102 | ||
| Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor | Q28509287 | ||
| Multiple essential functions of neuregulin in development | Q28587914 | ||
| Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail | Q28590093 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects | Q34580448 | ||
| Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q34595917 | ||
| ErbB2 pathways in heart and neural diseases | Q35066245 | ||
| HER-2/neu and topoisomerase IIalpha in breast cancer | Q35130680 | ||
| Monoclonal antibody therapy for breast cancer: herceptin | Q35875271 | ||
| Statins and cancer prevention | Q36337970 | ||
| Statin use and breast cancer: prospective results from the Women's Health Initiative. | Q36480676 | ||
| Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer | Q36593165 | ||
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 | ||
| The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice | Q37359529 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Requirement for neuregulin receptor erbB2 in neural and cardiac development | Q41269625 | ||
| Apoptosis in adriamycin cardiomyopathy and its modulation by probucol | Q43567484 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. | Q44465520 | ||
| New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity | Q44524623 | ||
| Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy | Q45175895 | ||
| retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: | Q46761542 | ||
| Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation. | Q51546024 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Long-Term Trends in the Incidence of and Survival with Heart Failure | Q57073236 | ||
| Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre | Q61624905 | ||
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer | Q71059676 | ||
| Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy | Q73105701 | ||
| Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species | Q74014516 | ||
| Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience | Q80112164 | ||
| Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment | Q81419131 | ||
| Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 | Q83305244 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 324-335 | |
| P577 | publication date | 2008-03-25 | |
| P1433 | published in | Nature Clinical Practice Oncology | Q15752073 |
| P1476 | title | Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects | |
| P478 | volume | 5 |
| Q26863244 | Cardiac effects of anticancer therapy in the elderly |
| Q33573823 | Cardiomyocyte autophagy and cancer chemotherapy |
| Q33574045 | Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention |
| Q37960873 | Cardiovascular toxicity of anti-angiogenic drugs |
| Q51224671 | Chemotherapy-induced Cardiotoxicity. |
| Q41130070 | Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies |
| Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
| Q57129922 | Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r |
| Q27022965 | Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines |
| Q33942611 | Nuclear imaging in detection and monitoring of cardiotoxicity |
| Q37310833 | Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects. |
| Q34441749 | Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment |
| Q34272044 | Targeting HER2 in breast cancer: overview of long-term experience |
| Q92979481 | Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo |
Search more.